Background: Vitiligo is a commonly acquired autoimmune pigmentary disorder. Some patients resist conventional treatments, leading to the search for combination therapies.
Aims: This study aimed to compare the efficacy of 308-nm excimer laser monotherapy versus combined treatment with topical bimatoprost 0.03% in patients with facial vitiligo.
Patients And Methods: A single-blind randomized clinical trial was conducted at Razi Hospital, Tehran, on 38 patients with facial vitiligo who had at least one facial vitiligo patch and had not undergone treatment in the past 3 months. The patients were randomly allocated to either the intervention group (n = 18) or the control group (n = 20). Both groups received 308-nm EL therapy twice weekly for 15 weeks, while the intervention group additionally applied 0.03% bimatoprost solution daily. The patients were visited at the end of every 5 weeks and after the 15th week. Efficacy was evaluated using the scale for improvement assessment (SAI), visual analog scale satisfaction (VASS), and visual analog scale improvement (VASI). Data analysis was performed using the Mann-Whitney and t-tests, with a significance level set at p < 0.05.
Results: Of the total patients, 27 (71.05%) were female and 11 (28.95%) were male. The male-to-female ratio was 50% in the intervention group and 33.33% in the control group. The mean VASI score, as the primary outcome, showed a significant increase over time in the intervention group (p ≤ 0.001), increasing from 4.53 to 7.20 (an increase of 2.67 units). Additionally, the intervention had a significant effect on the VASI outcome compared to the control (p ≤ 0.001; mean difference: 2.55 [1.63 to 3.47]). As the secondary outcomes, the mean VASS and SAI scores significantly decreased over time in the intervention group (p ≤ 0.05). The intervention also significantly affected the VASS and SAI outcomes compared to the control (p ≤ 0.001). The side effects of the intervention group were hypertrichosis in three patients and erythema burning in one patient.
Conclusions: Adding bimatoprost 0.03% to the treatment regimen may improve the outcomes of patients with facial vitiligo who are resistant to conventional treatments.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11836918 | PMC |
| http://dx.doi.org/10.1111/jocd.70020 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Value of tacrolimus 0.1% in the treatment of vitiligo in the era of targeted therapy.
Ann Dermatol Venereol
March 2025
Centre of Evidence of the French Society of Dermatology, Paris, France; Montpellier University, Montpellier, France. Electronic address:
Background: Vitiligo, a prevalent depigmenting condition, affects both adults and children, significantly impacting their quality of life. The standard treatment approach involves the application of topical corticosteroids in conjunction with narrow-band ultraviolet B (UVB) phototherapy. A novel topical treatment, ruxolitinib (a Janus kinase inhibitor), has recently received approval.
View Article and Find Full Text PDFCarboxytherapy in Dermatologic Surgery and Aesthetic Medicine: Current Knowledge and Future Perspectives-A Systematic Review.
Dermatol Surg
March 2025
Plastic Surgery Unit, Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy.
Background And Objective: Carboxytherapy (CXT) is a minimally invasive procedure based on percutaneous or subcutaneous microinjections of carbon dioxide. Due to the Bohr effect, it influences the hemoglobin dissociation curve, improving tissue oxygenation, angiogenesis, facilitating vascular perfusion, and lymphatic drainage. Recent evidence suggests unconventional applications in dermatologic surgery and aesthetic medicine; these are focused with the present review.
View Article and Find Full Text PDFA Case of Vogt-Koyanagi-Harada Disease: Diagnosis Based on the Presence of Vitiligo and Sunset Glow Fundus Without Ocular Symptoms.
Cureus
January 2025
Ophthalmology, Kochi Medical School, Nankoku, JPN.
Vogt-Koyanagi-Harada disease is an autoimmune disease affecting melanocytes. We report a case of Vogt-Koyanagi-Harada disease where the diagnosis was based on the presence of vertigo, vitiligo, and sunset glow fundus without ocular symptoms. The patient was a 68-year-old woman with a history of type 1 diabetes mellitus who developed vertigo three months prior and vitiligo on the face and arms two months prior.
View Article and Find Full Text PDFCongenital halo nevus associated with vitiligo aggravated by lasers targeting nevus of Ota: a case report.
J Cosmet Laser Ther
February 2025
Department of Dermatology, West China Hospital, Sichuan University, Sichuan, China.
An 11-year-old Chinese girl had bluish-gray hyperpigmented patches combined with two dark brown papules on her left face since birth, and she developed a hypopigmented patch within the bluish-gray patches after sun exposure at the age of eight. Her previous medical history suggested that the hypopigmented patch was sensitive to the treatment of tacrolimus ointment cream and 308-nm excimer laser, while the hyperpigmented patches were insensitive to the previous initial laser treatment. Based on the clinical manifestations and a positive result of Wood's lamp examination, she was diagnosed with nevus of Ota, congenital halo nevus, and vitiligo.
View Article and Find Full Text PDFThe Efficacy of 308-nm Excimer Laser With TopicalBimatoprost 0.03% for Facial Vitiligo.
J Cosmet Dermatol
February 2025
Department of Dermatology, Razi Hospital, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
Background: Vitiligo is a commonly acquired autoimmune pigmentary disorder. Some patients resist conventional treatments, leading to the search for combination therapies.
Aims: This study aimed to compare the efficacy of 308-nm excimer laser monotherapy versus combined treatment with topical bimatoprost 0.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!